NCT02860546View on ClinicalTrials.gov

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

September 7, 2017

Conditions
Refractory Metastatic Colorectal Cancer
Interventions
DRUG

TAS-102

One Arm Only (of TAS 102 plus nivolumab)

DRUG

nivolumab

One Arm Only (of TAS 102 plus nivolumab)

Trial Locations (3)

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

80218

Sarah Cannon Research Institute at HealthONE, Denver

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY

NCT02860546 - A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | Biotech Hunter | Biotech Hunter